Trial Profile
A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 15 Jan 2015 New trial record